Apple Hit with Rare Sell Rating, J&J's Ketamine-Derived Nasal Spray Gets FDA Approved for Depression
The Rundown
00:00
Market Movements and Breakthrough Medications
This chapter examines the FDA's approval of Johnson & Johnson's Spravato for severe depression, emphasizing its quick effectiveness. It also analyzes recent stock market shifts, including notable investments and the S&P 500's performance during presidential terms.
Transcript
Play full episode
